25 XP   0   0   10

Ligand Pharmaceuticals Incorporated
Buy, Hold or Sell?

Let's analyse Ligand together

PenkeI guess you are interested in Ligand Pharmaceuticals Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ligand Pharmaceuticals Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ligand Pharmaceuticals Incorporated

I send you an email if I find something interesting about Ligand Pharmaceuticals Incorporated.

Quick analysis of Ligand (30 sec.)










What can you expect buying and holding a share of Ligand? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$39.55
Expected worth in 1 year
$62.78
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$23.23
Return On Investment
33.2%

For what price can you sell your share?

Current Price per Share
$69.89
Expected price per share
$67.72 - $94.57
How sure are you?
50%

1. Valuation of Ligand (5 min.)




Live pricePrice per Share (EOD)

$69.89

Intrinsic Value Per Share

$-40.50 - $25.34

Total Value Per Share

$-0.95 - $64.89

2. Growth of Ligand (5 min.)




Is Ligand growing?

Current yearPrevious yearGrowGrow %
How rich?$702.3m$597.4m$104.8m14.9%

How much money is Ligand making?

Current yearPrevious yearGrowGrow %
Making money$52.1m-$5.2m$57.3m110.0%
Net Profit Margin39.7%-2.7%--

How much money comes from the company's main activities?

3. Financial Health of Ligand (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#74 / 1007

Most Revenue
#184 / 1007

Most Profit
#88 / 1007

Most Efficient
#47 / 1007

What can you expect buying and holding a share of Ligand? (5 min.)

Welcome investor! Ligand's management wants to use your money to grow the business. In return you get a share of Ligand.

What can you expect buying and holding a share of Ligand?

First you should know what it really means to hold a share of Ligand. And how you can make/lose money.

Speculation

The Price per Share of Ligand is $69.89. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ligand.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ligand, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $39.55. Based on the TTM, the Book Value Change Per Share is $5.81 per quarter. Based on the YOY, the Book Value Change Per Share is $-12.66 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ligand.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps2.944.2%2.944.2%-1.88-2.7%7.2010.3%5.387.7%
Usd Book Value Change Per Share5.818.3%5.818.3%-12.66-18.1%3.254.6%3.725.3%
Usd Dividend Per Share0.000.0%0.000.0%0.280.4%0.290.4%0.150.2%
Usd Total Gains Per Share5.818.3%5.818.3%-12.38-17.7%3.545.1%3.865.5%
Usd Price Per Share71.42-71.42-66.80-73.87-71.51-
Price to Earnings Ratio24.32-24.32--35.45--71.80--94.30-
Price-to-Total Gains Ratio12.30-12.30--5.40-14.10-340.12-
Price to Book Ratio1.81-1.81-1.98-1.85-5.67-
Price-to-Total Gains Ratio12.30-12.30--5.40-14.10-340.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share69.89
Number of shares14
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.29
Usd Book Value Change Per Share5.813.25
Usd Total Gains Per Share5.813.54
Gains per Quarter (14 shares)81.3149.61
Gains per Year (14 shares)325.23198.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1032531516182188
2065064033364386
3097696549546584
401301129066728782
501626161582910980
60195119409910921178
702277226511512741376
802602259013214561574
902927291514816381772
1003252324016518201970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%10.020.00.033.3%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%18.011.01.060.0%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%4.00.06.040.0%6.00.024.020.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%18.011.01.060.0%

Fundamentals of Ligand

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Fundamental data was last updated by Penke on 2024-04-11 13:18:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ligand Pharmaceuticals Incorporated.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ligand earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ligand to the Biotechnology industry mean.
  • A Net Profit Margin of 39.7% means that $0.40 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 39.7%. The company is making a huge profit. +2
  • The TTM is 39.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ39.7%TTM39.7%0.0%
TTM39.7%YOY-2.7%+42.4%
TTM39.7%5Y115.9%-76.1%
5Y115.9%10Y102.0%+13.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ39.7%-207.2%+246.9%
TTM39.7%-218.5%+258.2%
YOY-2.7%-282.4%+279.7%
5Y115.9%-432.2%+548.1%
10Y102.0%-593.8%+695.8%
1.1.2. Return on Assets

Shows how efficient Ligand is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ligand to the Biotechnology industry mean.
  • 6.3% Return on Assets means that Ligand generated $0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 6.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 6.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.3%TTM6.3%0.0%
TTM6.3%YOY-0.7%+6.9%
TTM6.3%5Y10.5%-4.3%
5Y10.5%10Y11.8%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3%-13.2%+19.5%
TTM6.3%-12.6%+18.9%
YOY-0.7%-11.5%+10.8%
5Y10.5%-13.7%+24.2%
10Y11.8%-15.5%+27.3%
1.1.3. Return on Equity

Shows how efficient Ligand is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ligand to the Biotechnology industry mean.
  • 7.4% Return on Equity means Ligand generated $0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 7.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.4%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.4%TTM7.4%0.0%
TTM7.4%YOY-0.9%+8.3%
TTM7.4%5Y19.0%-11.6%
5Y19.0%10Y25.3%-6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4%-16.7%+24.1%
TTM7.4%-15.8%+23.2%
YOY-0.9%-14.4%+13.5%
5Y19.0%-19.0%+38.0%
10Y25.3%-19.9%+45.2%

1.2. Operating Efficiency of Ligand Pharmaceuticals Incorporated.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ligand is operating .

  • Measures how much profit Ligand makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ligand to the Biotechnology industry mean.
  • An Operating Margin of 11.9% means the company generated $0.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 11.9%. The company is operating less efficient.
  • The TTM is 11.9%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.9%TTM11.9%0.0%
TTM11.9%YOY-13.0%+24.9%
TTM11.9%5Y5.4%+6.4%
5Y5.4%10Y23.0%-17.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9%-286.5%+298.4%
TTM11.9%-229.1%+241.0%
YOY-13.0%-288.4%+275.4%
5Y5.4%-480.7%+486.1%
10Y23.0%-624.7%+647.7%
1.2.2. Operating Ratio

Measures how efficient Ligand is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.93 means that the operating costs are $0.93 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.925. The company is less efficient in keeping operating costs low.
  • The TTM is 0.925. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.925TTM0.9250.000
TTM0.925YOY0.985-0.059
TTM0.9255Y0.925+0.000
5Y0.92510Y0.736+0.189
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9253.231-2.306
TTM0.9253.307-2.382
YOY0.9853.774-2.789
5Y0.9255.667-4.742
10Y0.7367.558-6.822

1.3. Liquidity of Ligand Pharmaceuticals Incorporated.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ligand is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 14.15 means the company has $14.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 14.148. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.148. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.148TTM14.1480.000
TTM14.148YOY2.668+11.480
TTM14.1485Y19.812-5.664
5Y19.81210Y12.983+6.829
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.1483.890+10.258
TTM14.1484.182+9.966
YOY2.6685.343-2.675
5Y19.8126.135+13.677
10Y12.9836.453+6.530
1.3.2. Quick Ratio

Measures if Ligand is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ligand to the Biotechnology industry mean.
  • A Quick Ratio of 21.27 means the company can pay off $21.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 21.271. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.271. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.271TTM21.2710.000
TTM21.271YOY2.501+18.771
TTM21.2715Y23.804-2.532
5Y23.80410Y15.581+8.222
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.2713.528+17.743
TTM21.2714.059+17.212
YOY2.5015.390-2.889
5Y23.8046.138+17.666
10Y15.5816.488+9.093

1.4. Solvency of Ligand Pharmaceuticals Incorporated.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ligand assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ligand to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Ligand assets are financed with 15.7% credit (debt) and the remaining percentage (100% - 15.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.157. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.157. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.157TTM0.1570.000
TTM0.157YOY0.217-0.060
TTM0.1575Y0.340-0.183
5Y0.34010Y0.435-0.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1570.339-0.182
TTM0.1570.337-0.180
YOY0.2170.273-0.056
5Y0.3400.368-0.028
10Y0.4350.391+0.044
1.4.2. Debt to Equity Ratio

Measures if Ligand is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ligand to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.6% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.186. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.186. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.186TTM0.1860.000
TTM0.186YOY0.276-0.090
TTM0.1865Y0.576-0.390
5Y0.57610Y1.499-0.922
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1860.388-0.202
TTM0.1860.403-0.217
YOY0.2760.342-0.066
5Y0.5760.432+0.144
10Y1.4990.461+1.038

2. Market Valuation of Ligand Pharmaceuticals Incorporated

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ligand generates.

  • Above 15 is considered overpriced but always compare Ligand to the Biotechnology industry mean.
  • A PE ratio of 24.32 means the investor is paying $24.32 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The EOD is 23.796. Based on the earnings, the company is fair priced.
  • The MRQ is 24.317. Based on the earnings, the company is fair priced.
  • The TTM is 24.317. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD23.796MRQ24.317-0.521
MRQ24.317TTM24.3170.000
TTM24.317YOY-35.452+59.769
TTM24.3175Y-71.803+96.120
5Y-71.80310Y-94.304+22.501
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD23.796-2.249+26.045
MRQ24.317-2.553+26.870
TTM24.317-2.669+26.986
YOY-35.452-4.107-31.345
5Y-71.803-6.247-65.556
10Y-94.304-6.499-87.805
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The EOD is -290.505. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -296.864. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -296.864. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-290.505MRQ-296.864+6.360
MRQ-296.864TTM-296.8640.000
TTM-296.864YOY9.862-306.726
TTM-296.8645Y-56.167-240.698
5Y-56.16710Y-11.195-44.972
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-290.505-2.858-287.647
MRQ-296.864-3.288-293.576
TTM-296.864-3.552-293.312
YOY9.862-5.560+15.422
5Y-56.167-8.326-47.841
10Y-11.195-8.881-2.314
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ligand is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.81 means the investor is paying $1.81 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The EOD is 1.767. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.806. Based on the equity, the company is underpriced. +1
  • The TTM is 1.806. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.767MRQ1.806-0.039
MRQ1.806TTM1.8060.000
TTM1.806YOY1.979-0.174
TTM1.8065Y1.853-0.048
5Y1.85310Y5.669-3.816
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7671.929-0.162
MRQ1.8062.090-0.284
TTM1.8062.091-0.285
YOY1.9792.881-0.902
5Y1.8533.545-1.692
10Y5.6693.936+1.733
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ligand Pharmaceuticals Incorporated.

3.1. Institutions holding Ligand Pharmaceuticals Incorporated

Institutions are holding 94.122% of the shares of Ligand Pharmaceuticals Incorporated.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc16.73120.005429623141212304.267
2023-12-31Vanguard Group Inc10.59860.00291876514246531.3313
2023-12-31HHG PLC7.58620.0572134315412810.0955
2023-12-31Macquarie Group Ltd5.57660.0815987354-4464-0.4501
2023-12-31State Street Corporation3.77450.0023668284450297.2248
2023-12-31Dimensional Fund Advisors, Inc.3.7350.0138661298469067.6345
2023-12-31Stephens Inv Mgmt Group LLC3.72450.688565943419187041.0361
2023-12-31Villere St Denis J & Co Llc2.41762.5177428051-10110-2.3074
2023-12-31Geode Capital Management, LLC2.09440.0028370815181945.1596
2023-12-31Pacer Advisors, INC.1.83970.065832572712104959.1412
2023-12-31abrdn PLC1.64030.045290418-29711-9.2809
2023-12-31Rice Hall James & Associates, LLC1.55891.1415276008-6953-2.4572
2023-12-31Chicago Capital, LLC1.30760.5954231511-128834-35.753
2023-12-31Cardinal Capital Management Llc1.25350.7282221927155287.5233
2023-12-31Northern Trust Corp1.24130.0028219780-101-0.0459
2023-12-31Amvescap Plc.1.21380.0037214901-3886-1.7762
2023-12-31Impax Asset Management Group PLC1.1590.05882052082088811.3325
2023-12-31Morgan Stanley - Brokerage Accounts1.12510.001319919441872.1471
2023-12-31William Blair Investment Management, LLC1.05810.03891873422754917.2404
2023-12-31Deutsche Bank AG1.050.00681858974966836.4592
Total 70.68596.060312515131+503973+4.0%

3.2. Funds holding Ligand Pharmaceuticals Incorporated

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28iShares Core S&P Small-Cap ETF6.25280.10071107084-4084-0.3675
2023-12-31Janus Henderson Triton D5.07140.940489790600
2023-12-31Janus Henderson US SMID Cap Growth5.07140.944489790600
2023-12-31Macquarie US Small Cap Core Equity4.18470.707974091400
2024-02-29Delaware Small Cap Core I4.13630.78947323432050.028
2024-02-29Vanguard Total Stock Mkt Idx Inv2.83060.002650117400
2024-02-29Vanguard Small Cap Index2.41170.024142700539920.9437
2024-03-28iShares Russell 2000 ETF2.32360.04594114061980.0482
2023-12-31Stephens SMID Select Growth2.17690.685138541910542637.6531
2023-12-31Janus Henderson US Small Cap Growth1.87140.776433134100
2023-12-31Janus Henderson Venture D1.87140.771133134100
2023-12-31Vanguard Explorer Inv1.70730.1013022797984635.8967
2024-02-29Vanguard Small Cap Value Index Inv1.64620.04352914719980.3436
2023-12-31Stephens Small Cap Growth1.53161.04312711768719747.3951
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.36680.01882420021520.0628
2024-01-31Impax Small Cap Institutional1.1592.248120520800
2023-12-31Impax US Small Cap Strategy Composite1.1592.15522052082088811.3325
2024-03-28iShares S&P Small-Cap 600 Value ETF1.14030.2043201902-2005-0.9833
2024-02-29DWS Small Cap Core S1.07311.953319000000
2024-01-31Fidelity Small Cap Index0.95820.0516965328401.7025
Total 49.943713.60538842738+295653+3.3%

3.3. Insider Transactions

Insiders are holding 5.928% of the shares of Ligand Pharmaceuticals Incorporated.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-05Stephen L SabbaSELL189374.3
2024-02-28Octavio EspinozaSELL14088.46
2023-09-22Todd C DavisBUY400059.38
2023-05-16John W KozarichSELL444477.2
2023-05-10Stephen L SabbaSELL640877.13
2023-05-08John W KozarichSELL640876.56

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ligand Pharmaceuticals Incorporated compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--5.8085.8080%-12.660+318%3.249+79%3.716+56%
Book Value Per Share--39.55439.5540%33.746+17%39.7230%27.303+45%
Current Ratio--14.14814.1480%2.668+430%19.812-29%12.983+9%
Debt To Asset Ratio--0.1570.1570%0.217-28%0.340-54%0.435-64%
Debt To Equity Ratio--0.1860.1860%0.276-33%0.576-68%1.499-88%
Dividend Per Share----0%0.283-100%0.294-100%0.147-100%
Eps--2.9372.9370%-1.884+164%7.198-59%5.376-45%
Free Cash Flow Per Share---0.241-0.2410%6.774-104%2.341-110%2.682-109%
Free Cash Flow To Equity Per Share---3.617-3.6170%-8.814+144%-11.427+216%-2.215-39%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--25.340--------
Intrinsic Value_10Y_min---40.504--------
Intrinsic Value_1Y_max--3.297--------
Intrinsic Value_1Y_min--0.735--------
Intrinsic Value_3Y_max--9.329--------
Intrinsic Value_3Y_min---1.930--------
Intrinsic Value_5Y_max--14.665--------
Intrinsic Value_5Y_min---9.112--------
Market Cap1237423417.000-2%1268204940.0001268204940.0000%1182714040.000+7%1336275186.048-5%1445041967.950-12%
Net Profit Margin--0.3970.3970%-0.027+107%1.159-66%1.020-61%
Operating Margin--0.1190.1190%-0.130+210%0.054+118%0.230-48%
Operating Ratio--0.9250.9250%0.985-6%0.925+0%0.736+26%
Pb Ratio1.767-2%1.8061.8060%1.979-9%1.853-3%5.669-68%
Pe Ratio23.796-2%24.31724.3170%-35.452+246%-71.803+395%-94.304+488%
Price Per Share69.890-2%71.42071.4200%66.800+7%73.872-3%71.5140%
Price To Free Cash Flow Ratio-290.505+2%-296.864-296.8640%9.862-3110%-56.167-81%-11.195-96%
Price To Total Gains Ratio12.034-2%12.29712.2970%-5.397+144%14.104-13%340.118-96%
Quick Ratio--21.27121.2710%2.501+751%23.804-11%15.581+37%
Return On Assets--0.0630.0630%-0.007+111%0.105-40%0.118-47%
Return On Equity--0.0740.0740%-0.009+112%0.190-61%0.253-71%
Total Gains Per Share--5.8085.8080%-12.377+313%3.543+64%3.863+50%
Usd Book Value--702357000.000702357000.0000%597485000.000+18%719645600.000-2%527744100.000+33%
Usd Book Value Change Per Share--5.8085.8080%-12.660+318%3.249+79%3.716+56%
Usd Book Value Per Share--39.55439.5540%33.746+17%39.7230%27.303+45%
Usd Dividend Per Share----0%0.283-100%0.294-100%0.147-100%
Usd Eps--2.9372.9370%-1.884+164%7.198-59%5.376-45%
Usd Free Cash Flow---4272000.000-4272000.0000%119927000.000-104%40786200.000-110%55412700.000-108%
Usd Free Cash Flow Per Share---0.241-0.2410%6.774-104%2.341-110%2.682-109%
Usd Free Cash Flow To Equity Per Share---3.617-3.6170%-8.814+144%-11.427+216%-2.215-39%
Usd Market Cap1237423417.000-2%1268204940.0001268204940.0000%1182714040.000+7%1336275186.048-5%1445041967.950-12%
Usd Price Per Share69.890-2%71.42071.4200%66.800+7%73.872-3%71.5140%
Usd Profit--52154000.00052154000.0000%-5219000.000+110%146078000.000-64%115396000.000-55%
Usd Revenue--131314000.000131314000.0000%196245000.000-33%182278600.000-28%154937300.000-15%
Usd Total Gains Per Share--5.8085.8080%-12.377+313%3.543+64%3.863+50%
 EOD+3 -5MRQTTM+0 -0YOY+27 -85Y+12 -2310Y+14 -21

4.2. Fundamental Score

Let's check the fundamental score of Ligand Pharmaceuticals Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.796
Price to Book Ratio (EOD)Between0-11.767
Net Profit Margin (MRQ)Greater than00.397
Operating Margin (MRQ)Greater than00.119
Quick Ratio (MRQ)Greater than121.271
Current Ratio (MRQ)Greater than114.148
Debt to Asset Ratio (MRQ)Less than10.157
Debt to Equity Ratio (MRQ)Less than10.186
Return on Equity (MRQ)Greater than0.150.074
Return on Assets (MRQ)Greater than0.050.063
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Ligand Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.434
Ma 20Greater thanMa 5075.480
Ma 50Greater thanMa 10074.604
Ma 100Greater thanMa 20073.037
OpenGreater thanClose70.000
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets833,064
Total Liabilities130,707
Total Stockholder Equity700,913
 As reported
Total Liabilities 130,707
Total Stockholder Equity+ 700,913
Total Assets = 833,064

Assets

Total Assets833,064
Total Current Assets237,429
Long-term Assets595,635
Total Current Assets
Cash And Cash Equivalents 22,954
Short-term Investments 147,355
Net Receivables 39,312
Inventory 23,969
Other Current Assets 3,839
Total Current Assets  (as reported)237,429
Total Current Assets  (calculated)237,429
+/-0
Long-term Assets
Property Plant Equipment 9,455
Goodwill 103,370
Long Term Investments 48,321
Intangible Assets 366,897
Long-term Assets Other 21,530
Long-term Assets  (as reported)595,635
Long-term Assets  (calculated)549,573
+/- 46,062

Liabilities & Shareholders' Equity

Total Current Liabilities16,782
Long-term Liabilities113,925
Total Stockholder Equity700,913
Total Current Liabilities
Short-term Debt 410
Accounts payable 14,894
Other Current Liabilities 256
Total Current Liabilities  (as reported)16,782
Total Current Liabilities  (calculated)15,560
+/- 1,222
Long-term Liabilities
Capital Lease Obligations 6,165
Long-term Liabilities Other 2,961
Long-term Liabilities  (as reported)113,925
Long-term Liabilities  (calculated)9,126
+/- 104,799
Total Stockholder Equity
Common Stock18
Retained Earnings 503,016
Accumulated Other Comprehensive Income -817
Other Stockholders Equity 198,696
Total Stockholder Equity (as reported)700,913
Total Stockholder Equity (calculated)700,913
+/-0
Other
Capital Stock18
Cash and Short Term Investments 170,309
Common Stock Shares Outstanding 17,757
Current Deferred Revenue1,222
Liabilities and Stockholders Equity 833,064
Net Debt -16,789
Net Invested Capital 700,913
Net Working Capital 220,647
Property Plant and Equipment Gross 31,717
Short Long Term Debt Total 6,165



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-31
> Total Assets 
46,700
93,600
102,100
107,400
156,000
134,600
113,422
117,473
270,609
301,255
332,466
332,466
326,053
173,278
171,448
113,699
75,559
122,350
104,260
104,713
258,029
533,929
601,585
671,021
1,260,803
1,469,307
1,362,285
1,301,383
762,668
833,064
833,064762,6681,301,3831,362,2851,469,3071,260,803671,021601,585533,929258,029104,713104,260122,35075,559113,699171,448173,278326,053332,466332,466301,255270,609117,473113,422134,600156,000107,400102,10093,60046,700
   > Total Current Assets 
41,600
73,000
85,400
84,100
78,000
56,700
44,649
53,574
83,753
130,157
172,824
172,824
235,557
109,943
93,929
68,166
37,019
32,230
23,823
24,881
185,158
215,572
163,053
237,021
870,540
1,123,645
500,559
464,751
263,601
237,429
237,429263,601464,751500,5591,123,645870,540237,021163,053215,572185,15824,88123,82332,23037,01968,16693,929109,943235,557172,824172,824130,15783,75353,57444,64956,70078,00084,10085,40073,00041,600
       Cash And Cash Equivalents 
7,600
16,000
34,800
62,300
32,800
29,900
9,224
20,741
42,423
59,030
92,310
92,310
158,401
76,812
28,753
16,032
3,346
7,041
12,381
15,979
167,336
200,219
141,048
201,661
718,381
1,011,532
47,619
19,522
45
22,954
22,9544519,52247,6191,011,532718,381201,661141,048200,219167,33615,97912,3817,0413,34616,03228,75376,812158,40192,31092,31059,03042,42320,7419,22429,90032,80062,30034,80016,0007,600
       Short-term Investments 
0
0
0
0
0
17,300
14,439
16,947
21,825
40,004
20,182
20,182
13,447
17,596
51,918
37,200
19,351
10,000
2,767
4,340
7,133
102,791
122,296
181,041
46,191
58,335
363,567
321,586
167
147,355
147,355167321,586363,56758,33546,191181,041122,296102,7917,1334,3402,76710,00019,35137,20051,91817,59613,44720,18220,18240,00421,82516,94714,43917,30000000
       Net Receivables 
1,200
2,300
3,100
0
0
1,700
12,824
9,798
7,356
19,051
30,847
30,847
11,521
10,467
12,100
9,782
993
6,110
8,916
6,551
12,956
10,952
17,907
29,473
55,850
41,748
59,064
91,646
35,038
39,312
39,31235,03891,64659,06441,74855,85029,47317,90710,95212,9566,5518,9166,1109939,78212,10010,46711,52130,84730,84719,0517,3569,79812,8241,700003,1002,3001,200
       Other Current Assets 
32,800
54,700
47,500
21,800
39,000
2,100
2,511
2,332
7,308
3,810
17,713
17,713
9,518
15,535
11
58,384
36,026
24,819
829
959
4,597
2,768
2,175
1,514
20,418
4,734
3,822
4,671
3,399
3,839
3,8393,3994,6713,8224,73420,4181,5142,1752,7684,59795982924,81936,02658,3841115,5359,51817,71317,7133,8107,3082,3322,5112,10039,00021,80047,50054,70032,800
   > Long-term Assets 
5,100
20,600
16,700
23,300
78,000
77,900
68,773
63,899
186,856
171,098
0
159,642
90,496
63,335
77,519
45,533
38,540
90,120
80,437
79,832
72,871
318,357
438,532
434,000
390,263
345,662
861,726
836,632
499,067
595,635
595,635499,067836,632861,726345,662390,263434,000438,532318,35772,87179,83280,43790,12038,54045,53377,51963,33590,496159,6420171,098186,85663,89968,77377,90078,00023,30016,70020,6005,100
       Property Plant Equipment 
3,900
12,300
11,700
14,900
23,700
20,500
10,972
9,690
9,672
23,501
23,647
23,647
5,551
2,865
12,903
8,522
559
455
788
867
486
372
1,819
4,212
5,372
10,353
22,734
32,749
15,009
9,455
9,45515,00932,74922,73410,3535,3724,2121,8193724868677884555598,52212,9032,8655,55123,64723,64723,5019,6729,69010,97220,50023,70014,90011,70012,3003,900
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,375
700
700
14,894
68,150
65,337
62,961
60,585
276,912
314,543
306,439
305,677
784,992
734,996
448,128
103,370
103,370448,128734,996784,992305,677306,439314,543276,91260,58562,96165,33768,15014,8947007005,37500000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,207
0
7,417
29,728
8,345
6,438
0
0
0
0
3,000
48,321
48,3213,00000006,4388,34529,7287,41708,207000000000000000000
       Intangible Assets 
0
0
0
0
0
0
44,924
41,879
148,546
137,857
127,443
127,443
83,083
0
5,375
2,515
12,951
57,437
55,912
4,571
4,568
8,554
25,821
19,526
31,460
20,090
10,979
10,110
10,182
366,897
366,89710,18210,11010,97920,09031,46019,52625,8218,5544,5684,57155,91257,43712,9512,5155,375083,083127,443127,443137,857148,54641,87944,924000000
       Long-term Assets Other 
1,200
8,300
5,000
8,400
54,300
57,400
57,801
54,209
159,130
9,740
8,552
8,552
1,862
60,470
59,241
7,966
23,317
15,756
3,292
1,640
4,856
2,554
1,744
4,859
-600,746
9,542
18,701
23,252
14,218
21,530
21,53014,21823,25218,7019,542-600,7464,8591,7442,5544,8561,6403,29215,75623,3177,96659,24160,4701,8628,5528,5529,740159,13054,20957,80157,40054,3008,4005,0008,3001,200
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
0
0
189,083
123,891
0
0
0
0
0
0
0
0000000123,891189,083008000000000000000000
> Total Liabilities 
20,400
65,500
67,600
73,100
167,400
160,200
168,547
175,348
196,594
230,527
407,783
407,783
298,701
144,163
181,813
109,955
82,550
113,704
77,775
55,100
233,621
229,538
230,732
252,374
699,889
702,075
652,760
479,754
165,183
130,707
130,707165,183479,754652,760702,075699,889252,374230,732229,538233,62155,10077,775113,70482,550109,955181,813144,163298,701407,783407,783230,527196,594175,348168,547160,200167,40073,10067,60065,50020,400
   > Total Current Liabilities 
8,100
15,700
13,800
21,700
26,900
20,700
28,415
31,726
30,535
54,049
216,712
216,712
170,810
50,968
70,614
52,172
35,630
43,643
35,439
28,939
22,779
20,836
227,129
238,868
82,249
17,002
100,111
41,665
98,810
16,782
16,78298,81041,665100,11117,00282,249238,868227,12920,83622,77928,93935,43943,64335,63052,17270,61450,968170,810216,712216,71254,04930,53531,72628,41520,70026,90021,70013,80015,7008,100
       Short-term Debt 
1,300
2,400
2,600
2,800
3,200
4,100
3,478
5,367
2,087
2,479
2,924
2,924
37,750
1,528
1,829
9,873
8,034
16,197
14,835
9,109
334
934
212,910
224,529
26,433
1,242
6,593
46
77,410
410
41077,410466,5931,24226,433224,529212,9109343349,10914,83516,1978,0349,8731,8291,52837,7502,9242,9242,4792,0875,3673,4784,1003,2002,8002,6002,4001,300
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
195,908
201,985
212,910
224,529
26,433
0
0
0
76,695
0
076,69500026,433224,529212,910201,985195,90800000000000000000000
       Accounts payable 
2,300
3,900
4,100
10,700
12,400
5,400
3,827
5,385
11,979
18,691
17,352
17,352
12,259
12,682
14,627
16,945
8,597
11,065
16,277
15,501
22,123
10,422
9,131
9,636
23,383
2,420
3,784
8,403
5
14,894
14,89458,4033,7842,42023,3839,6369,13110,42222,12315,50116,27711,0658,59716,94514,62712,68212,25917,35217,35218,69111,9795,3853,8275,40012,40010,7004,1003,9002,300
       Other Current Liabilities 
4,500
9,400
7,100
8,200
11,300
11,200
21,110
12,245
11,786
30,315
196,436
43,908
60,856
34,794
41,893
18,663
17,297
15,141
3,841
4,213
172
10,414
5,088
4,530
29,147
11,201
60,299
22,220
21,040
256
25621,04022,22060,29911,20129,1474,5305,08810,4141724,2133,84115,14117,29718,66341,89334,79460,85643,908196,43630,31511,78612,24521,11011,20011,3008,2007,1009,4004,500
   > Long-term Liabilities 
12,300
49,800
53,800
51,400
140,500
139,500
140,132
143,622
166,059
176,478
0
191,071
127,891
93,195
111,199
57,783
46,920
70,061
42,336
26,161
210,842
208,702
3,603
13,506
617,640
685,073
552,649
438,089
66,373
113,925
113,92566,373438,089552,649685,073617,64013,5063,603208,702210,84226,16142,33670,06146,92057,783111,19993,195127,891191,0710176,478166,059143,622140,132139,500140,50051,40053,80049,80012,300
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,406
0
3,071
39,628
29,563
18,859
609,864
638,959
442,293
320,717
0
0
00320,717442,293638,959609,86418,85929,56339,6283,071019,406000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
0
0
189,083
123,891
0
0
0
0
0
0
0
0000000123,891189,083008000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,628
29,563
18,859
0
0
0
0
0
0
00000018,85929,56339,628000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
8,427
6,864
6,714
6,426
7,634
7,307
113,390
80,223
96,676
77,547
38,204
38,909
28,168
25,063
12,142
3,330
3,603
13,506
7,776
61,752
104,713
101,878
56,032
0
056,032101,878104,71361,7527,77613,5063,6033,33012,14225,06328,16838,90938,20477,54796,67680,223113,3907,3077,6346,4266,7146,8648,427000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,094
0
3,183
0
0
3,525
0
32,937
64,598
59,095
0
0
0059,09564,59832,93703,525003,18303,094000000000000000000
> Total Stockholder Equity
26,300
28,100
34,500
34,300
-11,400
-25,600
-55,125
-57,875
74,015
70,728
0
-75,317
27,352
29,115
-10,365
3,744
-6,991
8,646
26,485
49,613
26,318
304,391
370,853
418,647
560,914
767,232
709,525
821,629
597,485
700,913
700,913597,485821,629709,525767,232560,914418,647370,853304,39126,31849,61326,4858,646-6,9913,744-10,36529,11527,352-75,317070,72874,015-57,875-55,125-25,600-11,40034,30034,50028,10026,300
   Common Stock
0
0
0
0
0
100
57
60
72
73
73
73
100
101
119
123
21
21
21
21
20
20
21
21
21
17
16
17
0
18
18017161721212120202121212112311910110073737372605710000000
   Retained Earnings 
-76,100
-140,300
-177,600
-277,700
-395,600
-470,300
-542,725
-585,720
-618,316
-655,778
-794,660
-794,660
-862,802
-581,512
-679,626
-681,574
-691,947
-681,771
-682,759
-671,339
-659,315
-402,010
-431,127
-400,924
-229,197
400,105
391,952
449,090
451
503,016
503,016451449,090391,952400,105-229,197-400,924-431,127-402,010-659,315-671,339-682,759-681,771-691,947-681,574-679,626-581,512-862,802-794,660-794,660-655,778-618,316-585,720-542,725-470,300-395,600-277,700-177,600-140,300-76,100
   Accumulated Other Comprehensive Income 
-4,400
-7,100
-11,000
-14,500
-17,800
-4,100
-2,030
-678
-43
-66
-41,097
229
-481
9
81
513
31
-4,771
-4,881
2,914
4,953
4,903
2,743
2,486
-1,024
-216
-801
-917
-1
-817
-817-1-917-801-216-1,0242,4862,7434,9034,9532,914-4,881-4,77131513819-481229-41,097-66-43-678-2,030-4,100-17,800-14,500-11,000-7,100-4,400
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
751,503
0
718,017
661,850
769,653
798,205
791,114
367,326
318,358
372,969
0
0
00372,969318,358367,326791,114798,205769,653661,850718,0170751,503000000000000000000
   Treasury Stock00000000000-42,280-42,280-42,225-42,134-42,134-40,521-911-911-911-911-911-911-911000000
   Other Stockholders Equity 
106,800
175,500
223,100
326,500
402,000
467,900
513,832
557,326
692,302
726,499
0
719,041
890,535
610,517
669,061
684,682
687,046
690,396
714,104
718,017
680,660
701,478
799,216
817,064
791,114
367,326
318,358
373,439
597,035
198,696
198,696597,035373,439318,358367,326791,114817,064799,216701,478680,660718,017714,104690,396687,046684,682669,061610,517890,535719,0410726,499692,302557,326513,832467,900402,000326,500223,100175,500106,800



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue131,314
Cost of Revenue-11,561
Gross Profit119,753119,753
 
Operating Income (+$)
Gross Profit119,753
Operating Expense-109,932
Operating Income9,8219,821
 
Operating Expense (+$)
Research Development24,537
Selling General Administrative52,790
Selling And Marketing Expenses0
Operating Expense109,93277,327
 
Net Interest Income (+$)
Interest Income7,041
Interest Expense-656
Other Finance Cost-109
Net Interest Income6,276
 
Pretax Income (+$)
Operating Income9,821
Net Interest Income6,276
Other Non-Operating Income Expenses0
Income Before Tax (EBT)63,660-44,018
EBIT - interestExpense = 14,924
61,995
52,810
Interest Expense656
Earnings Before Interest and Taxes (EBIT)15,58064,316
Earnings Before Interest and Taxes (EBITDA)51,223
 
After tax Income (+$)
Income Before Tax63,660
Tax Provision-49,606
Net Income From Continuing Ops21,09714,054
Net Income52,154
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses121,493
Total Other Income/Expenses Net53,839-6,276
 

Technical Analysis of Ligand
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ligand. The general trend of Ligand is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ligand's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ligand Pharmaceuticals Incorporated.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 81.73 < 94.57.

The bearish price targets are: 68.25 > 68.14 > 67.72.

Tweet this
Ligand Pharmaceuticals Incorporated Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ligand Pharmaceuticals Incorporated. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ligand Pharmaceuticals Incorporated Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ligand Pharmaceuticals Incorporated. The current macd is -1.3887547.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ligand price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ligand. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ligand price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ligand Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) ChartLigand Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ligand Pharmaceuticals Incorporated. The current adx is 23.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ligand shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Ligand Pharmaceuticals Incorporated Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ligand Pharmaceuticals Incorporated. The current sar is 76.97.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Ligand Pharmaceuticals Incorporated Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ligand Pharmaceuticals Incorporated. The current rsi is 38.43. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Ligand Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) ChartLigand Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ligand Pharmaceuticals Incorporated. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ligand price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ligand Pharmaceuticals Incorporated Daily Stochastic Oscillator ChartLigand Pharmaceuticals Incorporated Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ligand Pharmaceuticals Incorporated. The current cci is -84.97827016.

Ligand Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) ChartLigand Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ligand Pharmaceuticals Incorporated. The current cmo is -33.56091246.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ligand Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) ChartLigand Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ligand Pharmaceuticals Incorporated. The current willr is -84.51106353.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Ligand Pharmaceuticals Incorporated Daily Williams %R ChartLigand Pharmaceuticals Incorporated Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ligand Pharmaceuticals Incorporated. The current atr is 2.4727749.

Ligand Pharmaceuticals Incorporated Daily Average True Range (ATR) ChartLigand Pharmaceuticals Incorporated Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ligand Pharmaceuticals Incorporated. The current obv is 1,393,717.

Ligand Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) ChartLigand Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ligand Pharmaceuticals Incorporated. The current mfi is 33.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ligand Pharmaceuticals Incorporated Daily Money Flow Index (MFI) ChartLigand Pharmaceuticals Incorporated Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ligand Pharmaceuticals Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Ligand Pharmaceuticals Incorporated Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ligand Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.434
Ma 20Greater thanMa 5075.480
Ma 50Greater thanMa 10074.604
Ma 100Greater thanMa 20073.037
OpenGreater thanClose70.000
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ligand with someone you think should read this too:
  • Are you bullish or bearish on Ligand? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ligand? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ligand Pharmaceuticals Incorporated

I send you an email if I find something interesting about Ligand Pharmaceuticals Incorporated.


Comments

How you think about this?

Leave a comment

Stay informed about Ligand Pharmaceuticals Incorporated.

Receive notifications about Ligand Pharmaceuticals Incorporated in your mailbox!